Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/11690/3835
Autor(es): | Paula, Tania Maria Hendges de Castro, Mariane Schäffer Medeiros, Liciane Fernandes Paludo, Rodrigo Hernandes Couto, Fabricia Fritz Costa, Tainá Ramires da Fortes, Juliana Pereira Salbego, Maiara de Oliveira Behnck, Gabriel Schardosim Moura, Thielly Amaral Mesquita de Tarouco, Mariana Lenz Caumo, Wolnei Souza, Andressa de |
Título: | Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial |
Palavras-chave: | Fibromyalgia;Naltrexone;Pain;Transcranial direct current stimulation |
Data do documento: | 2022 |
Editor: | BRAZILIAN JOURNAL OF ANESTHESIOLOGY |
Citação: | CASTRO, M. S. et al. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial. BRAZILIAN JOURNAL OF ANESTHESIOLOGY, p. xx, 2022. Disponível em: https://www.sciencedirect.com/science/article/pii/S010400142200104X?via%3Dihub Acesso em: 22 fev. 2024. |
Resumo: | Introduction: Fibromyalgia is a complex, generalized, and diffuse chronic musculoskeletal pain. Pharmacological approaches are widely used to relieve pain and increase quality of life. LowDose Naltrexone (LDN) was shown to increase the nociceptive threshold in patients with fibromyalgia. Transcranial Direct Current Stimulation (tDCS) is effective for pain management. Objective: The purpose of this study was to evaluate the analgesic and neuromodulatory effects of a combination of LDN and tDCS in patients with fibromyalgia. Methods: This was a randomized, double-blinded, parallel, placebo/sham-controlled trial (NCT04502251; RBR-7HK8N) in which 86 women with fibromyalgia were included, and written informed consent was obtained from them. The patients were allocated into four groups: LDN + tDCS (n = 21), LDN + tDCS Sham (n = 22), placebo + tDCS (n = 22), and placebo+tDCS Sham (n = 21). The LDN or placebo (p.o.) intervention lasted 26 days; in the last five sessions, tDCS was applied (sham or active, 20 min, 2 mA). The following categories were assessed: sociodemographic, Visual Analog Pain Scale (VAS), Pain Catastrophizing Scale (PCS), State-Trait Anxiety Inventory (STAI), Fibromyalgia Impact Questionnaire (FIQ), Beck Depression Inventory (BDI-II), Profile of Chronic Pain Scale (PCP:S), Pain Pressure Threshold (PPT), and Conditioned Pain Modulation (CPM). Blood samples were collected to analyze BDNF serum levels. Results: At baseline, no significant difference was found regarding all measurements. VAS pain was significantly reduced in the LDN + tDCS (p = 0.010), LDN + tDCS Sham (p = 0.001), and placebo+tDCS Sham (p = 0.009) groups. In the PCP:S, the LDN+tDCS group showed reduced pain frequency and intensity (p = 0.001), effect of pain on activities (p = 0.014) and emotions (p = 0.008). Depressive symptoms reduced after all active interventions (p > 0.001). Conclusion: Combined LDN+tDCS has possible benefits in reducing pain frequency and intensity; however, a placebo effect was observed in pain using VAS, and further studies should be performed to analyze the possible association. |
Aparece nas coleções: | Artigo de Periódico (PPGSDH) |
Arquivos associados a este item:
Arquivo | Descrição | Tamanho | Formato | |
---|---|---|---|---|
1-s2.0-S010400142200104X-main.pdf | Open Access | 839,69 kB | Adobe PDF | Visualizar/Abrir |
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.